BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
NCT02608229
Terminated
In light of the central role of extracellular signal-regulated kinases (ERK) in pancreatic cancer, the investigators propose a phase I study to evaluate the ERK inhibitor BVD-523 at the recommended phase 2 dose in combination with nab-paclitaxel plus gemcitabine in patients with newly diagnosed metastatic pancreatic cancer. The primary endpoint will be maximum tolerated dose (MTD) or RP2D and safety. The secondary endpoints include safety, response rate, biochemical response, progression-free su... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2021
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
Register for Updates
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
NCT02562898
Completed
Gemcitabine and nab-paclitaxel is a standard regimen (NCCN, Category 1) for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). However, further improvement in treatment is needed. Increasingly, the nature of the immune infiltrate in PDAC appears to be tumor promoting. In preclinical studies, ibrutinib treatment, presumably by reprogramming B cells, results in increased CD8+ T cells to assist in tumor control. Preclinical studies of ibrutinib plus gemcitabine show superior antitumo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/13/2021
Locations: University of California, San Francisco, San Francisco, California +1 locations
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00951496
Completed
This randomized phase III trial studies bevacizumab and intravenous (given into a vein) chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given into the abdominal cavity) chemotherapy in treating patients with stage II-III ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block the ability of tumor cells to grow and spread by blocking the growth of new blood vessels necessary for tum... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/13/2021
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +502 locations
Conditions: Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Undifferentiated Carcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Stage II Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Register for Updates
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02574078
Completed
The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2021
Locations: Alabama Oncology, Birmingham, Alabama +132 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
NCT02155088
Completed
The main purpose of this study is to see primarily if BYL719 is safe to be given to patients in combination with gemcitabine and nab-paclitaxel. Gemcitabine and nab-paclitaxel is an FDA-approved regimen to treat pancreatic cancer. Secondary goals will be to find out the effect on tumor of this new drug combination of BYL719, gemcitabine and nab-paclitaxel. In the first part of the study, different doses of BYL719 will be tested. In the second part of the study, all patients will be started at th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2021
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Pancreatic Cancer
Register for Updates
Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
NCT00723125
Completed
In the MDACC/BrUOG neoadjuvant trial with weekly paclitaxel followed by Fluorouracil Plus Doxorubicin and Cyclophosphamide (FAC), the pathologic complete response (pCR) rate in HER2(-) patients was 20%. The investigators' goal is to develop an induction chemotherapy regimen that will have a pCR rate above 30% in patients with HER2(-) disease. Based on a 1-sided 95% confidence interval using normal approximation with an expected pCR rate of at least 35%, approximately 28 patients are required for... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/06/2021
Locations: Bridgeport Hospital, Bridgeport, Connecticut +4 locations
Conditions: Breast Cancer
Register for Updates
Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma
NCT02468557
Terminated
The primary objective of this study is to evaluate the safety of single agent idelalisib and to evaluate safety and define the maximum tolerated dose (MTD) of idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2021
Locations: Scottsdale Healthcare Clinical Research Institute, Scottsdale, Arizona +8 locations
Conditions: Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
Register for Updates
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
NCT02041429
Completed
This phase I/II research study is evaluating a combination of drugs called paclitaxel and ruxolitinib as a possible treatment for inflammatory breast cancer. Ruxolitinib is a newly discovered drug that has been shown to block a pathway (called the IL6/JAK/Stat pathway) that may be important in cancer, including breast cancer. Blocking this pathway may stop cancer cells from growing. Ruxolitinib has been approved by the FDA for patients with bone marrow disease, and this is the first study using... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2021
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Recurrent Breast Cancer, Metastatic Breast Cancer
Register for Updates
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
NCT03563170
Withdrawn
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2021
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Register for Updates
Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
NCT00945191
Completed
This trial assessed the effect of treatment with CS-1008 in combination with paclitaxel/carboplatin on response in patients with locally advanced or metastatic ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2021
Locations: Univ. Alabama, Birmingham, Alabama +2 locations
Conditions: Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
Register for Updates
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
NCT02501902
Completed
This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD expansion cohort(s). Approximately 30-60 patients are expected to be enrolled in the overall study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2021
Locations: Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona +25 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer
NCT01716195
Completed
The purpose of this study is to determine whether human papillomavirus (HPV)-positive head and neck cancer can be treated with a less aggressive regimen of radiation therapy and chemotherapy (paclitaxel) after initially receiving two cycles of chemotherapy (carboplatin/paclitaxel).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2021
Locations: University of California Comprehensive Cancer Center, Sacramento, California
Conditions: Head and Neck Cancer
Register for Updates